American Family Children's Hospital

The mission of the UW Carbone Cancer Center (UWCCC) Developmental Therapeutics (DT) Program is to discover new targets and therapeutic agents, translate and advance these discoveries through clinical trials and use information and resources from these clinical trials to understand mechanisms of response and resistance toward potentially superior therapeutic approaches.


Program Leaders

Glenn Liu, MD Shigeki Miyamoto, PhDJing Zhang, PhD


The overarching goal of the DT Program is to bridge scientific discovery in our laboratories (bench) with our clinical research (bedside) enterprise, and provide opportunities for our patients to participate in clinical trials. The DT Program focuses on the discovery of cancer relevant pathways and molecular targets, development of new molecular and imaging tools and therapy related assays and biomarkers, and testing of novel chemical and biological (including immune-based) treatments for cancer.

  • Aim 1: Investigate cancer cell-intrinsic and -extrinsic mechanisms to identify new molecular targets for cancer therapy
  • Aim 2: Develop chemical and biological agents with anticancer activity, as well as therapy predictive assays and biomarkers.
  • Aim 3: Advance promising new therapies from Phase I into Phase II and Phase III clinical trials.